|
|
|
| The efficacy and safety of Bevacizumab combined with Paclitaxel and Carboplatin for recurrent ovarian cancer |
| LIU Hong-mei1 LIU Shi-zhuan2 |
1.Department of Oncology,Yangchun City People′s Hospital,Guangdong Province,Yangchun 529600,China;
2.Intensive Care Unit,Yangchun City People′s Hospital,Guangdong Province,Yangchun 529600,China |
|
|
|
|
Abstract ObjectiveTo explore the efficacy and safety of Bevacizumab combined with Paclitaxel and Carboplatin for recurrent ovarian cancer.MethodsFrom June 2014 to January 2016,82 recurrent ovarian cancer patients were randomly divided into treatment group(41 cases)and control group(41 cases),the control group were treated by Paclitaxel and Carboplatin,and the treatment group were treated by Bevacizumab combined with Paclitaxel and Carboplatin.The clinical efficacy(such as overall response rate,complete response rate,partial response rate),progression free survival,overall survival and the adverse reaction rate were comparatively analyzed.ResultsThe overall response rate of treatment group was 85.37%,and the overall response rate of control group was 65.85%with signifant difference.The progression free survival and overall survival of treatment group were significantly higher than those of control group（P＜0.05）.There was no statistical difference in the adverse reaction rate between two groups（P＞0.05）.ConclusionComparing with the treatment of Paclitaxel and Carboplatin,combined with Bevacizumab in the treatment of recurrent ovarian cancer have an obviously improved efficacy,significantly improved progression-free survival and overall survival in patients,there is no significant difference in safety.
|
|
|
|
|
|
| [1] |
卢淮武，王东雁，林仲秋.《2015美国肿瘤综合协作网卵巢癌输卵管癌原发性腹膜癌临床实践指南（第1版）》解读[J].中国实用妇科与产科杂志，2015，31（5）：378-384.
|
| [2] |
张艳，张菊新.复发性卵巢癌诊疗进展[J].中华实用诊断与治疗杂志，2013，27（10）：942-943.
|
| [3] |
林仲秋，吴妙芳，李晶，等.《FIGO 2015妇癌报告》解读连载三——卵巢癌、输卵管癌、腹膜癌诊治指南解读[J].中国实用妇科与产科杂志，2015，31（12）：1074-1081.
|
| [4] |
Liu XH，Man YN，Wu XZ.Recurrence season impacts the survival of epithelial ovarian cancer patients[J].Asian Pac J Cancer Prev，2014，15（4）：1627-1632.
|
| [5] |
Naumann RW，Coleman RL.Management strategies for recurrent platinum-resistant ovarian cancer[J].Drugs，2011，71（11）：1397-1412.
|
| [6] |
陈小芸，张栋栋，范维，等.贝伐单抗治疗卵巢癌疗效及不良反应的系统评价[J].现代妇产科进展，2014，23（7）：548-552.
|
| [7] |
张西愿，徐小博，马向东，等.贝伐珠单抗治疗上皮性卵巢癌的临床研究进展[J].现代妇产科进展，2014，23（6）：489-492.
|
| [8] |
邹玲芝，曹兰琴，易红.Annexin A1在紫杉醇耐药卵巢癌中的表达及其临床意义[J].中南大学学报（医学版），2014，39（8）：784-789.
|
| [9] |
Jayson GC，Kerbel R，Ellis LM，et al.Antiangiogenic therapy in oncology:current status and future directions[J].Lancet，2016，388（10043）：518-529.
|
| [10] |
Scambia G，Salutari V，Ferrandina G.Combining targeted therapies in ovarian cancer[J].Lancet Oncol，2014，15（11）：1179-1181.
|
| [11] |
欧盟批准贝伐珠单抗注射液用于卵巢癌治疗[J].世界临床药物，2012，33（2）：124.
|
| [12] |
Borderud SP，Li Y，Burkhalter JE，et al.Electronic cigarette use among patients with cancer:characteristics of electronic cigarette users and their smoking cessation outcomes[J]. Cancer，2014，120（22）：3527-3535.
|
| [13] |
Liu JF，Barry WT，Birrer M，et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:a randomised phase 2 study[J].Lancet Oncol，2014，15（11）：1207-1214.
|
| [14] |
Pignata S，Scambia G，Katsaros D，et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer（MITO-7）：a randomised，multicentre，open-label，phase 3 trial[J].Lancet Oncol，2014，15（4）：396-405.
|
| [15] |
Pujade-Lauraine E，Hilpert F，Weber B，et al.Bevacizumab combinedwithchemotherapyforplatinum-resistantrecurrent ovarian cancer：the aurelia open-label randomized phaseⅢtrial[J].J Clin Oncol，2014，32 （13）：1302-1308.
|
|
|
|
